56875-59-3

Usage

Uses

Used in Pharmaceutical Industry:
6-methoxy-2-naphthalenesulfonyl chloride (SALTDATA: FREE) is used as a synthetic intermediate for the development of various pharmaceutical compounds. Its unique structure allows for the creation of a wide range of molecules with potential therapeutic applications, making it a valuable asset in drug discovery and design.
Used in Chemical Synthesis:
In the field of chemical synthesis, 6-methoxy-2-naphthalenesulfonyl chloride (SALTDATA: FREE) serves as a key building block for the production of various specialty chemicals. Its reactivity with different functional groups enables the formation of a diverse array of chemical products, including dyes, pigments, and other industrial chemicals.
Used in Research and Development:
6-methoxy-2-naphthalenesulfonyl chloride (SALTDATA: FREE) is also employed in research and development settings, where it is used to explore new chemical reactions and investigate the properties of novel compounds. Its unique structure and reactivity make it an attractive candidate for studying various aspects of organic chemistry and materials science.

Upstream product

• 832-85-9 2-hydroxy-8-naphthalenesulfonic acid monosodium salt 
• 149353-39-9 sodium 6-methoxy-2-naphthalenesulfonate 
• 135-76-2 sodium 2-naphthol-6-sulfonate 

Downstream Products

• 186550-66-3 6-Methoxy-naphthalene-2-sulfonic acid [(S)-1-(3-cyano-benzyl)-2-oxo-pyrrolidin-3-yl]-amide 
• 250723-66-1 3-(4-cyano-2-fluoro-phenyl)-N-cyclopentyl-2-(6-methoxy-naphthalene-2-sulfonylamino)-N-methyl-propionamide 
• 386768-87-2 N'-(4-cyanobenzyl)-6-methoxy-N'-[(4-methyl-1-piperidinyl)carbonyl]-2-naphthalenesulfonohydrazide 
• 386768-88-3 N'-(3-cyanobenzyl)-6-methoxy-N-[(4-methyl-1-piperidinyl)carbonyl]-2-naphthalenesulfonohydrazide 
• 439926-88-2 N'-(3-Cyanobenzyl)-6-methoxy-N'-[(2-methyl-1-piperidinyl)carbonyl]-2-naphthalenesulfonohydrazide 
• 439926-95-1 N'-(1-Azepanylcarbonyl)-N'-(3-cyanobenzyl)-6-methoxy-2-naphthalenesulfonohydrazide 
• 1360630-60-9 6-methoxy-N-(3'-methoxybiphenyl-4-yl)naphthalene-2-sulfonamide 
• 1360630-54-1 N-(biphenyl-4-yl)-6-methoxynaphthalene-2-sulfonamide 
• 1360630-57-4 6-methoxy-N-(3'-(trifluoromethyl)biphenyl-4-yl)naphthalene-2-sulfonamide 
• 1360630-65-4 N-(3',4'-dimethoxybiphenyl-4-yl)-6-methoxynaphthalene-2-sulfonamide 
• 1360630-61-0 6-methoxy-N-(3'-nitrobiphenyl-4-yl)naphthalene-2-sulfonamide 
• 1360630-63-2 methyl 4'-(6-methoxynaphthalene-2-sulfonamido)biphenyl-4-carboxylate 
• 1360630-59-6 N-(3'-chlorobiphenyl-4-yl)-6-methoxynaphthalene-2-sulfonamide 
• 1360630-58-5 N-(3'-fluorobiphenyl-4-yl)-6-methoxynaphthalene-2-sulfonamide 

Relevant academic research and scientific papers

SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS

The present invention relates to sulfonylated tetrahydroazolopyrazines, methods for the preparation thereof, medicinal products containing these compounds and the use of substituted indole compounds for the preparation of medicinal products (Formula I).

SUBSTITUTED SULFONAMIDE COMPOUNDS

Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.

Novel naphthalene-N-sulfonyl-D-glutamic acid derivatives as inhibitors of MurD, a key peptidoglycan biosynthesis enzyme

Mur ligases have essential roles in the biosynthesis of peptidoglycan, and they represent attractive targets for the design of novel antibacterials. MurD (UDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase) is the second enzyme in the series of Mur ligases, and it catalyzes the addition of D-glutamic acid (D-Glu) to the cytoplasmic intermediate UDP-N-acetylmuramoyl-L-alanine (UMA). Because of the high binding affinity of D-Glu toward MurD, we synthesized and biochemically evaluated a series of N-substituted D-Glu derivatives as potential inhibitors of MurD from E. coli, which allowed us to explore the structure-activity relationships. The substituted naphthalene-N-sulfonyl-D-Glu inhibitors, which were synthesized as potential transitionstate analogues, displayed IC50 values ranging from 80 to 600 μM. In addition, the high-resolution crystal structures of MurD in complex with four novel inhibitors revealed details of the binding mode of the inhibitors within the active site of MurD. Structure-activity relationships and cocrystal structures constitute an excellent starting point for further development of novel MurD inhibitors of this structural class.

Novel compounds useful for bradykinin B1 receptor antagonism

Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the

Bispiperidines as antithrombotic agents

Novel compounds which are inhibitors of the binding of fibrinogen to the Gp IIb/IIIa platelet receptors, and which can be used therepeutically as antithrombotic agents

Use of oxido-squalene cyclase inhibitors to lower blood cholesterol

PCT No. PCT/GB96/01985 Sec. 371 Date Feb. 13, 1998 Sec. 102(e) Date Feb. 13, 1998 PCT Filed Aug. 14, 1996 PCT Pub. No. WO97/06802 PCT Pub. Date Feb. 27, 1997A compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein G, T1, T2 and T3 are selected from CH and N; provided that T2 and T3 are not both CH; A is selected from a direct bond and (1-4C)alkylene; X is selected from oxy, thio, sulphinyl, sulphonyl, carbonyl, carbonylamino, N-di-(1-6C)alkylcarbonylamino, sulphonamido, methylene, (1-4C)alkylmethylene and di-(1-6C)alkylmethylene, and when T2 is CH, X may also be selected from aminosulphonyl and oxycarbonyl; and Q is selected from (5-7C)cycloalkyl, a heterocyclic moiety containing up to 4 heteroatoms selected from nitrogen, oxygen and sulphur, phenyl, naphthyl, phenyl(1-4C)alkyl and phenyl(2-6C)alkenyl; for the manufacture of a medicament for treating diseases or medical conditions in which an inhibition of oxido-squalene cyclase is desirable.

Aminoheterocyclic derivatives as antithrombotic or anticoagulant

The invention concerns compounds of formula (I), wherein each of G1, G2 and G6 is CH or n; m is 1 or 2; R1 includes hydrogen, halogeno and (1-4C)alkyl; M1 is a group of formula: NR2 -L1 -T1 R3, in which R2 and R3 together form a (1-4C)alkylene group, L1 includes (1-4C)alkylene, and T1 is CH or N; A may be a direct link; M2 is a group of the formula: (T2 R4)r -L2 T3 R5 in which R is 0 or 1, each of T2 and T3 is CH or N, each of R4 and R5 is hydrogen or (1-4C)alkyl, or R4 and R5 together form a (1-4C)alkylene group, and L2 includes (1-4C)alkylene; M3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocycle moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.

Metal-Ammonia Reduction and Reductive Alkylation of N-Alkylnaphthalenesulfonamides. A New Route to Substituted Naphthalenes

Conditions have been found for 1,4-reduction of aromatic sulfomamides (conveniently monitored by electrical conductivity), using metals in THF/liquid ammonia on the pre-formed N-lithium salts (BuLi), without concomitant C-S reductive cleavage.The resultin